New combo therapy aims to outsmart advanced liver cancer

NCT ID NCT05168163

Recruiting now Disease control Sponsor: Academic and Community Cancer Research United Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This phase II trial tests whether adding the immunotherapy drug atezolizumab to a targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The study enrolls 122 adults whose cancer has progressed after prior treatment with atezolizumab plus bevacizumab. Researchers will measure overall survival and progression-free survival to see if the combination improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (immunotherapy) plus cabozantinib or lenvatinib (kinase inhibitors)
What this could lead to: If successful, this could provide a new treatment option for advanced liver cancer patients whose disease has progressed after initial immunotherapy.
What could go wrong: This is a phase II trial with only 122 participants, so results are preliminary. Adding atezolizumab may increase side effects without improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA METASTATIC HEPATOCELLULAR CARCINOMA STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IIIB HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IVA HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IVB HEPATOCELLULAR CARCINOMA AJCC V8 UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Allegheny General Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15212, United States
Carle Cancer Center NCI Community Oncology Research Program
RECRUITING

Urbana, Illinois, 61801, United States
Cleveland Clinic Weston Florida
WITHDRAWN

Weston, Florida, 33331, United States
Duke University Medical Center
COMPLETED

Durham, North Carolina, 27710, United States
Froedtert and the Medical College of Wisconsin LAPS
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Mayo Clinic in Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida
WITHDRAWN

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Michigan Cancer Research Consortium NCORP
RECRUITING

Ann Arbor, Michigan, 48106, United States
Rapid City Regional Hospital
RECRUITING

Rapid City, South Dakota, 57701, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
University Hospitals Cleveland Medical Center
WITHDRAWN

Cleveland, Ohio, 44106, United States
University Medical Center New Orleans
RECRUITING

New Orleans, Louisiana, 70112, United States
University of Chicago Comprehensive Cancer Center
NOT_YET_RECRUITING

Chicago, Illinois, 60637, United States
University of Michigan Comprehensive Cancer Center
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.